Merck Discontinues Development of SARS-CoV-2/COVID-19 Vaccine Candidates
Company continues Development of Two Investigational Therapeutic Candidates
26-Jan-2021 -
Merck, known as MSD outside the United States and Canada, announced that the company is discontinuing development of its SARS-CoV-2/COVID-19 vaccine candidates, V590 and V591, and plans to focus its SARS-CoV-2/COVID-19 research strategy and production capabilities on advancing two therapeutic ...
coronaviruses
Covid-19
SARS-CoV-2
+2